生物系研究部動物施設(沼津支所内)

研究業績

Anti-CD133 Monoclonal Antibody CMab-43 Exerts Antitumor Activity in a Mouse Xenograft Model of Colon Cancer.
Y. Kato, T. Ohishi, S. Yamada, S. Itai, Y. Furusawa, M. Sano, T. Nakamura, M. Kawada and MK. Kaneko
Monoclon. Antib. Immunodiagn. Immunother. 2019, doi:10.1089/mab.2019.0002.

Calpain-10 regulates actin dynamics by proteolysis of microtubule-associated protein 1B.
T. Hatta, SI. Iemura, T. Ohishi, H. Nakayama, H. Seimiya, T. Yasuda, K. Iizuka, M. Fukuda, J. Takeda, T. Natsume and Y. Horikawa.
Sci Rep. 2018, 8:16756, doi: 10.1038/s41598-018-35204-x.

The mouse–canine chimeric anti-dog podoplanin antibody P38B exerts antitumor activity in mouse xenograft models.
Y. Kato, T. Ohishi, M. Kawada, N. Maekawa, S. Konnai, S. Itai, S. Yamada and MK. Kaneko
Biochem Biophys Rep. 2019, 17, 23-26

Dihydroorotate dehydrogenase as a target for the development of novel Helicobacter pylori-specific antimicrobials.
T. Ohishi, DK. Inaoka, K. Kita and M. Kawada
Chem. Pharm. Bull. 2018, 66, 1-4

MERIT40-dependent recruitment of tankyrase to damaged DNA and its implication for cell sensitivity to DNA-damaging anticancer drugs
K. Okamoto, T. Ohishi, M. Kuroiwa, S. Iemura, T. Natsume and H. Seimiya
Oncotarge 2018, 9, 35844-35855

Podocalyxin is crucial for the growth of oral squamous cell carcinoma cell line HSC-2.
S. Itai, S. Yamada, M. Kaneko, M. Sano, T. Nakamura, M. Yanaka, S. Handa, K. Hisamatsu, Y. Nakamura, Y. Furusawa, M. Fukui, T. Ohishi, M. Kawada, H. Harada and Y. Kato
Biochem Biophys Rep. 2018, 15, 93-96

Beneficial effects of green tea catechins on neurodegenerative diseases.
M. Pervin, K. Unno, T. Ohishi, H. Tanabe, N. Miyoshi and Y. Nakamura
Molecules 2018, 23, 1297

Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma.
S. Itai, T. Ohishi, MK. Kaneko, S. Yamada, S. Abe, T. Nakamura, M. Yanaka, YW. Chang, SI. Ohba, Y. Nishioka, M. Kawada, H. Harada and Y. Kato
Oncotarget 2018, 9, 22480-22497

Monotherapy with a novel intervenolin derivative, AS-1934, is an effective treatment for Helicobacter pylori infection.
T. Ohishi, T. Masuda, H. Abe, C. Hayashi, H. Adachi, S. Ohba, M. Igarashi, T. Watanabe, H. Mimuro, E. Amalia, DK. Inaoka, K. Mochizuki, K. Kita, M. Shibasaki and M. Kawada
Helicobacter 2018, 23, e12470

In vivo efficacy of β-lactam/tripropeptin C in a mouse septicemia model and the mechanism of reverse β-lactam resistance in methicillin-resistant Staphylococcus aureus mediated by tripropeptin C.
H. Hashizume1, Y. Takahashi, T. Masuda, S. Ohba, T. Ohishi, M. Kawada and M. Igarashi
J. Antibiot. 2018, 71, 79-85

Tankyrase-binding protein TNKS1BP1 regulates actin cytoskeleton rearrangement and cancer cell invasion.
T. Ohishi, H. Yoshida, M. Katori, T. Migita, Y. Muramatsu, M. Miyake, Y. Ishikawa, A. Saiura, SI. Iemura, T. Natsume and H. Seimiya
Cancer Res. 2017, 77, 2328-2338

Epithelial-mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer.
T. Migita, A. Ueda, T. Ohishi, M. Hatano, H. Seimiya, S. Horiguchi, F. Koga and F. Shibasaki.
Laboratory Investigation 2017, 97, 567-576

Antipodocalyxin antibody chPcMab-47 exerts antitumor activity in mouse xenograft models of colorectal adenocarcinomas.
MK. Kaneko, A. Kunita, S. Yamada, T. Nakamura, M. Yanaka, N. Saidoh, YW. Chang, S. Handa, S. Ogasawara, T. Ohishi, S. Abe, S. Itai, H. Harada, M. Kawada, Y. Nishioka, M. Fukayama and Y. Kato
Monoclon Antib Immunodiagn Immunother. 2017, 36, 157-162

A novel monoclonal antibody targeting coxsackie virus and adenovirus receptor inhibits tumor growth in vivo
M. Kawada, H. Inoue, M. Kajikawa, M. Sugiura, S. Sakamoto, S. Urano, C. Karasawa, I. Usami, M. Futakuchi and T. Masuda.
Sci. Rep. 2017, 7:40400 doi: 10.1038/srep40400.

Anti-inflammatory action of green tea.
T. Ohishi, S. Goto, P. Monira, M. Isemura and Y. Nakamura.
Antiinflamm Antiallergy Agents Med Chem. 2016, 15, 74-90.

SF-1 deficiency causes lipid accumulation in Leydig cells via suppression of STAR and CYP11A1.
M. Hatano, T. Migita, T. Ohishi, Y. Shima, Y. Ogawa, Kl. Morohashi, Y. Hasegawa and F. Shibasaki.
Endocrine. 2016, 54, 484-496.

Anti-cancer effects of green tea by either anti- or pro-oxidative mechanisms.
S. Hayakawa, K. Saito, N. Miyoshi, T. Ohishi, Y. Oishi, Y. Oishi, M. Miyoshi and Y. Nakamura
Asian Pac J Cancer Prev. 2016, 17, 1649-1654.

Bladder cancer stem-like cells: their origin and therapeutic perspectives.
T. Ohishi, F. Koga and T. Migita.
Int. J. Mol. Sci. 2016, 17, 43

Report on the use of non-clinical studies in the regulatory evalution of oncology drugs.
Y. Hayakawa, M. Kawada, H. Nishikawa, T. Ochiya, H. Saya, H. Seimiya, R. Yao, M. Hayashi, C. Kai, A. Matsuda, T. Naoe, A. Ohtsu, T. Okazaki, H. Saji, M. Sata, H. Sugimura, Y. Sugiyama, M. Toi and T. Irimura.
Cancer Sci. 2016,107,189-202.

Novel autophagy inducers lentztrehaloses A, B and C
S. Wada, Y. Kubota, R. Sawa, M. Umekita, M. Hatano, S. Ohba, C. Hayashi, M. Igarashi and A. Nomoto.
J. Antibiot. 2015, 68, 521-529

New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice.
S. Sakamoto, H. Inoue, S. Ohba, Y. Kohda, I. Usami, T. Masuda, M. Kawada and A. Nomoto.
Cancer Science.2015 106,367-374

Antitumor effects of tyropeptin-boronic acid derivatives: new proteasome inhibitors.
I. Momose, H. Abe, T. Watanabe, S. Ohba, K. Yamazaki, S. Dan, T. Yamori, T. Masuda and
A. Nomoto
Cancer Sci. 2014, 105, 1609-1615.

Structure and biological properties of lentztrehalose: a novel trehalose analog.
S. Wada, S. Ohba, T. Someno, M. Hatano and A. Nomoto.
J. Antibiot. 2014, 67, 319-322.

Suppression of type II collagen-induced arthritis by ICM0301B, a new angiogenesis inhibitor.
H. Kumagai, T. Masuda, S. Ohba and D. Ikeda.
J. Antibiot. 2013, 66, 243-246.

Synthesis of intervenolin, an antitumor natural quinolone with unusual substituents.
H. Abe, M. Kawada, H. Inoue, S. Ohba, A. Nomoto, T. Watanabe and M. Shibasaki.
Org. Lett. 2013, 15, 2124-2127.

Structure-activity relationship study of intervenolin derivatives:
synthesis, antitumor and anti-Helicobacter Pylori activities.
H. Abe, M. Kawada, H. Inoue, S. Ohba, T. Masuda, C. Hayashi, M. Igarashi,
A. Nomoto, T. Watanabe and M. Shibasaki.
Tetrahedron 2013, 69, 7608-7617.

Intervenolin, a new antitumor compound with anti-Helicobacter pylori activity, from Nocardia sp. ML96-86F2.
M. Kawada, H. Inoue, S. Ohba, M. Hatano, M. Amemiya, C. Hayashi, I. Usami, H. Abe, T. Watanabe, N. Kinoshita, M. Igarashi, T. Masuda, D. Ikeda and A. Nomoto.
J. Antibiot. 2013, 66, 543-548.

Amycolamicin: a novel broad-spectrum antibiotic inhibiting bacterial topoisomerase.
R. Sawa, Y. Takahashi, H. Hashizume, K. Sasaki, Y. Ishizaki, M.Umekita, M. Hatano,
H. Abe, T. Watanabe, N. Kinoshita, Y. Homma, C. Hayashi, K. Inoue, S. Ohba,
T. Masuda, M. Arakawa, Y. Kobayashi, M. Hamada, M. Igarashi, H. Adachi,
Y. Nishimura and Y. Akamatsu.
Chem. Eur. J. 2012, 18, 15772-15781.

In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter.
I. Momose, D. Tatsuda, S. Ohba, T. Masuda, D. Ikeda and A. Nomoto.
Cancer Sci. 2012, 103, 1730-1736.

Citric acid inhibits a bacterial ceramidase and alleviates atopic dermatitis in an animal model.
H. Inoue, T. Someno, M. Kawada and D. Ikeda.
J. Antibiot. 2010, 63, 611-613.

NBRI16716A, a new antitumor compound against human prostate cancer cells, produced by Perisporiopsis melioloides Mer-f16716.
M. Kawada, T. Someno, H. Inoue, S. Ohba, T. Masuda, T. Kato and D. Ikeda.
J. Antibiot. 2010, 63, 319-323.

NBRI17671, a new antitumor compound, produced by Acremonium sp. CR17671.
M. Kawada, I. Usami, T. Someno, T. Watanabe, H. Abe, H. Inoue, S. Ohba, T. Masuda,
Y. Tabata, S. Yamaguchi and D. Ikeda.
J. Antibiot. 2010, 63, 237-243.

Mitochondrial inhibitors show preferential cytotoxicity to human pancreatic cancer PANC-1 cells under glucose-deprived conditions.
I. Momose, S. Ohba, D. Tatsuda, M. Kawada, T. Masuda, G. Tsujiuchi, T. Yamori, H. Esumi and D. Ikeda.
Biochem. Biophys. Res. Commun. 2010, 392, 460-466.

Rubratoxin A specifically and potently inhibits protein phosphatase 2A and suppresses cancer metastasis.
S. Wada, I. Usami, Y. Umezawa, H. Inoue, S. Ohba, T. Someno, M. Kawada and D. Ikeda.
Cancer Sci. 2010, 101, 743-750.

Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells.
M. Kawada, H. Inoue, S. Ohba, T. Masuda, I. Momose and D. Ikeda.
Int. J. Cancer 2010, 126, 810-818.

Ceramidastin, a novel bacterial ceramidase inhibitor, produced by Penicillium sp.
Mer-f17067.
H. Inoue, T. Someno, T. Kato, H. Kumagai, M. Kawada and D. Ikeda.
J. Antibiot. 2009, 62, 63-67.

Phthoxazolin A inhibits prostate cancer growth by modulating tumor-stromal cell interactions.
M. Kawada, H. Inoue, I. Usami and D. Ikeda.
Cancer Sci. 2009, 100, 150-157.

Transforming growth factor-β1 modulates tumor-stromal cell interactions of prostate cancer through insulin-like growth factor-I.
M. Kawada, H. Inoue, M. Arakawa and D. Ikeda.
Anticancer Res. 2008, 28, 721-730.